Journal of Shandong University (Health Sciences) ›› 2019, Vol. 57 ›› Issue (4): 34-41.doi: 10.6040/j.issn.1671-7554.0.2018.1301

Previous Articles     Next Articles

Clinical observation of the effects of idebenone on Parkinsons disease

ZHANG Xiaotao1,2, HE Tianqi1,2, ZHU Meijia2, TANG Jiyou2, ZHAO Zhangning2, MAO Fei2, FANG Yuqing2, LIU Xiaomin2, MA Gaoting2, ZHANG Xiaoyu2, ZHANG Xiao2, WANG Min3, LI Xiuhua2   

  1. 1. Weifang Medical University, Weifang 261000, Shandong, China;
    2. Department of Neurology, Qianfoshan Hospital Affiliated to Shandong University, Jinan 250014, Shandong, China;
    3. Key Laboratory of Animal Resistance Biology of Shandong Province, College of Life Sciences, Shandong Normal University, Jinan 250014, Shandong, China
  • Published:2022-09-27

PDF (PC)

394

Abstract: Objective To investigate the effects of idebenone(IDE)on the motor and non-motor symptoms in patients with Parkinsons disease(PD)and to explore its neuroprotective effect. Methods A total of 200 PD patients were randomly divided into the IDE group(IDE+routine treatment)and routine group(routine treatment). The scores of Unified Parkinsons Disease Rating-III(on-stimulation), UPDRS-III(off-stimulation), Montreal Cognitive Assessment(MOCA), Pittsburgh Sleep Quality Index(PSQI), and Non-Motor Symptoms Scale for Parkinsons Disease(NMSS)were monitored before treatment and 3, 6, 9, 12, 15 and 18 months after treatment. Furthermore, changes of plasma superoxide dismutase(SOD)and uric acid were detected before treatment and 6, 12 and 18 months after treatment. Results (1) In month 3, 6, 9, 12, 15 and 18 after treatment, the score of UPDRS-III(on-stimulation)in the IDE group versus that in the routine group was 16.64±6.08 vs 16.79±6.44, 14.69±5.33 vs 15.64±6.16, 12.81±4.73 vs 14.58±5.86, 11.04±3.95 vs 13.54±5.56, 9.664±3.43 vs 12.41±5.11 and 8.471±3.09 vs 11.16±4.65, respectively. In month 3 and 6, there was no difference between the two groups (P>0.05). In month 9, 12, 15 and 18, the score was significantly lower in the IDE group than in the routine group(P<0.05). (2) In month 3, 6, 9, 12, 15 and 18 after treatment, the score of UPDRS-III(off-stimulation)in the IDE group versus that in the routine group was 23.09±8.63 vs 19.85±7.20, 21.10±7.13 vs 19.63±6.85, 19.30±6.24 vs 19.13±6.57, 17.39±5.37 vs 18.32±6.28, 15.65±4.78 vs 17.35±5.97 and 14.05±4.25 vs 16.10±5.64, respectively. In month 3, 6, 9 and 12, there was no difference between the two groups(P>0.05). In month 15 and 18, the score was significantly lower in the IDE group than in the routine group(P<0.05). (3) In month 3, 6, 9, 12, 15 and 18 after treatment, the MOCA score in the IDE group versus that in the routine group was 21.68±4.59 vs 22.13±4.64, 23.02±3.60 vs 22.69±4.23, 24.39±2.66 vs 23.40±3.69, 25.30±2.12 vs 24.20±3.18, 25.94±1.81 vs 25.17±2.66 and 24.72±2.23 vs 24.27±2.94, respectively. In month 3, 6 and 18, there was no significant difference between the two groups(P>0.05). In month 9, 12 and 15, the score was significantly higher in the IDE group than in the routine group(P<0.05). (4) In month 3, 6, 9, 12, 15 and 18 after treatment, the PSQI score in the IDE group versus that in the routine group was 6.36±4.26 vs 6.12±4.19, 5.33±3.84 vs 5.25±3.85, 4.59±3.45 vs 4.50±3.50, 3.32±2.92 vs 3.51±3.27, 2.71±2.38 vs 3.26±3.03 and 2.20±2.02 vs 3.04±2.84, respectively. In month 3, 6, 9, 12 and 15, there was no difference between the two groups(P>0.05). In month 18, the score was significantly lower in the IDE group than in the routine group(P<0.05). (5) In month 3, 6, 9, 12, 15 and 18 after treatment, the NMSS score in the IDE group versus that in the routine group was 54.6±31.87 vs 54.56±33.26, 52.01±30.11 vs 52.42±32.02, 46.84±30.76 vs 50.38±30.65, 41.20±29.60 vs 46.97±28.05, 38.77±26.67 vs 43.18±24.65, 36.63±25.39 vs 41.03±23.48, respectively. There was no significant difference between the two groups(P>0.05). (6) In month 6, 12 and 18 after treatment, the level of uric acid in the IDE group versus the routine group was(253.81±111.86)vs (217.82±103.24)μmol/L,(272.56±111.04)vs (198.90±102.36)μmol/L, and(280.12±111.09)μmol/L vs(191.97±101.81)μmol/L, respectively. The level of uric acid was significantly higher in the IDE group than in the routine group(P<0.05). (7) In month 6, 12 and 18, the SOD level in the IDE group versus that in the routine group was(154.45±39.96)vs (126.47±41.30)U/mL,(162.45±42.08)vs (119.36±39.71)U/mL, and(172.90±41.78)vs (112.17±37.17)U/mL, respectively. The SOD level was significantly higher in the IDE group than in the routine group(P<0.05). Conclusion IDE can improve the motor and non-motor symptoms in PD patients and slow down the progression of the disease. It has a certain neuroprotective effect on PD.

Key words: Parkinsons disease, Idebenone, Oxidative stress, Motor symptom, Non-motor symptom

CLC Number: 

  • R574
[1] Sarkar S, Raymick J. Neuroprotective and Therapeutic Strategies against Parkinsons Disease: Recent Perspectives[J]. Int J Mol Sci, 2016, 17(6): 904.
[2] Liu Y, Schubert DR. The specificity of neuroprotection by antioxidants[J]. J Biomed Sci, 2009, 16(1): 98-111.
[3] Bentinger M, Tekle M. Coenzyme Q-biosynthesis and functions[J]. Biochem Biophys Res Commun, 2010, 396(1): 74-79.
[4] Geromel V, Darin N, Chrétien D, et al. Coenzyme Q(10)and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits[J]. Mol Genet Metab, 2002, 77(1-2):21-30.
[5] Leonardi A, Crasci L, Panico A. Antioxidant activity of idebenone-loaded neutral and cationic solid-lipid nanoparticles[J]. Pharm Dev Technol, 2015, 20(6): 716-723.
[6] 崔亚欢, 陈乃耀. 帕金森病的发病机制研究[J]. 中华老年心脑血管病杂志, 2019, 21(1): 106-110.
[7] 陈东万, 曹红元, 严家川, 等. 帕金森病患者血清氧化应激标志物的变化特点[J]. 现代生物医学进展, 2015, 15(34): 6671-6674. CHEN Dongwan, CAO Hongyuan, YAN Jiachuan, et al. Characteristics of oxidative stress biomarkers in serum of patients with Parkinsons disease[J]. Progress in Modern Biomedicine, 2015, 15(34): 6671-6674.
[8] 王引明, 孔亮, 胡玲玲. 帕金森病患者尿酸、超氧化物歧化酶和血清营养指标的变化[J]. 中国现代药物应用, 2013, 7(23): 76-77.
[9] 李晓鹏, 赵鹏, 钱进. 血尿酸与帕金森病的相关性及其作用机制研究进展[J]. 神经损伤与功能重建, 2018, 13(9): 464-466.
[10] 雷革胜, 苗建亭, 李柱一. 帕金森病血抗氧化系统变化及L-多巴的影响[J]. 中国神经免疫学和神经病学杂志, 2002, 9(3): 172-173, 176. LEI Gesheng, MIAO Jianting, Li Zhuyi. The change of blood antioxidant system in parkinson disease and the influence of L-dopa[J]. Chinese Journal of Neuroimmunology and Neurology, 2002, 9(3): 172-173, 176.
[11] 许继平, 李玉莲, 蔺新英, 等. 帕金森病患者血液抗氧化功能的变化及多巴制剂与Vit E对其影响的研究[J]. 中风与神经疾病杂志, 2000, 17(1): 46-48. XU Jiping, LI Yulian, LIN Xinying, et al. The change of blood antioxidant function in Parkinson disease and the effect of Dopa and Vit E on it[J]. Journal of Apoplexy and Nervous Diseases, 2000, 17(1): 46-48.
[12] 王丽君, 罗蔚锋, 王恒会, 等. 帕金森病患者血尿酸水平[J]. 中华神经科杂志, 2008, 41(3): 157-158.
[13] Rhodes SL, Buchanan DD, Ahmed I, et al. Pooled analysis of iron-related genes in Parkinsons disease: association with transferring[J]. Neurobiol Dis, 2014, 62(2): 172-178.
[14] Annanmaki T, Pessala-Driver A, Hokkanen L, et al. Uric acid associates with cognition in Parkinsons disease[J]. Parkinsonism Relat Disord, 2008, 14(7): 576-578.
[15] Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease[J]. Arch Neurol, 2008, 65(6): 716-723.
[16] 王大勇. 血清尿酸水平与帕金森病运动障碍及左旋多巴治疗的效果观察[J]. 中国实用医药, 2018, 13(17): 141-142.
[17] Martignoni E, Blandini F, Godi L, et al. Peripheral markers of oxidative stress in Parkinsons disease the role of L-DOPA[J]. Free Radic Biol Med, 1999, 27(3-4): 428-437.
[18] Wieland E, Schütz E, Armstrong VW, et al. Idebenone protects hepatic microsomes against oxygen radical-mediated damage in organ preservation solutions[J]. Transplantation, 1995, 60(5): 444-451.
[19] Parkinson MH, Schulz JB, Giunti P. Co-enzyme Q10 and idebenone use in Friedreichs ataxia[J]. J Neurochem, 2013, 126(Suppl 1): 125-141.
[20] Gillis JC, Benefield P. Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders[J]. Drugs Aging, 1994, 5(2): 133-152.
[21] Curti D, Izzo E, Brambilla L, et al. Effect of a ubiquinone-like molecule on oxidative energy metabolism in rat cortical synaptosomes at different ages[J]. Neurochem Res, 1995, 20(9): 1001-1006.
[22] Sterky FH, Hoffman AF, Milenkovic D, et al. Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons[J]. Hum Mol Genet, 2012, 21(5): 1078-1089.
[23] Horvath TL, Diano S, Leranth C, et al. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinsons disease[J]. Endocrinology, 2003, 144(7): 2757-2760.
[24] Yan A, Liu Z, Song L, et al. Idebenone Alleviates Neuroinflammation and Modulates Microglial Polarization in LPS-Stimulated BV2 Cells and MPTP-Induced Parkinsons Disease Mice[J]. Front Cell Neurosci, 2018, 12: 529.
[25] Di Prospero NA, Baker A, Jeffries N. Neurological effects of high-dose idebenone in patients with Friedreichs ataxia: a randomised, placebo-controlled trial[J]. Lancet Neurol, 2007, 6(10): 878-886.
[1] YU Haozhi, SHI Guidong, XU Guopeng, JIANG Yunpeng, FENG Shiqing, LIU Xinyu, QI Lei. Research progress of antioxidant carbon dot nanozymes to regulate the neuro-regeneration microenvironment [J]. Journal of Shandong University (Health Sciences), 2026, 64(2): 44-49.
[2] LI Xiang, ZHANG Yi, WANG Xuechun, XU Mengchao, WANG Yuelan. Research progress on oxidative stress in acute lung injury induced by traumatic brain injury [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 118-124.
[3] REN Yanhong, LI Xiuhua, ZHU Xiaoran, FANG Yuqing, ZHAO Zhangning, MAO Fei, WANG Yalin, ZHANG Yanqing, LIU Tianhao, XU Xinrong. Therapeutic efficacy of idebenone on cognitive impairment in patients with Parkinsons disease [J]. Journal of Shandong University (Health Sciences), 2024, 62(10): 106-114.
[4] HU Yanwen, ZHAO Huichen, MA Xiaoli, LIU Yuantao, ZHANG Yuchao. GLP-1 inhibits oxidative stress damage through cytochrome P450 surface oxidase pathway [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 10-16.
[5] YAN Congcong, CHEN Chen, XIE Qian, WANG Yanan, ZHANG Xinlu, ZHANG Yingchun, WU Bin. Effects of bisphenol A exposure on m6A modification level of KGN cells [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 17-23.
[6] LIU Yang, CHEN Guihai. Effects and mechanism of Hanjingtang on the oxidative stress induced by cold stimulation in aortic vascular smooth muscle cells [J]. Journal of Shandong University (Health Sciences), 2023, 61(8): 24-30.
[7] QI Shaojun, TANG Yanjin, ZHANG Zhengduo, WU Hong, ZHANG Jiacheng, QIN Chuan, LIU Rui, GAO Xibao. Protective effects of supplementing various trace elements on rats with high-sucrose diet [J]. Journal of Shandong University (Health Sciences), 2023, 61(7): 19-26.
[8] ZHANG Jiaying, SU Rongyun, WANG Yinghui, WANG Honggang, LIU Gang. ACE2 gene protects against renal ischemia-reperfusion injury by regulating the Nrf2/HO-1 signaling pathway [J]. Journal of Shandong University (Health Sciences), 2023, 61(4): 1-9.
[9] WU Hong, ZHANG Zhengduo, TANG Yanjin, QI Shaojun, GAO Xibao. Potential intervention effects of 5-methyltetrahydrofolate on atherosclerosis in rats [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 6-13.
[10] LIU Min, ZHANG Yuchao, MA Xiaoli, LIU Xinyu, SUN Lu, ZUO Dan, LIU Yuantao. Effects of orphan nuclear receptor NR4A1 on H2O2 induced injury of mouse renal podocytes [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 16-21.
[11] HU Na, SUN Miao, XING Shasha, XU Danxia, HAI Xiaoming, MA Ling, YANG Li, MIAN Yuchen, HE Rui, CHEN Dongmei, MA Huiming. Evening primrose oil resists oxidative stress in the ovaries of rats with polycystic ovary syndrome [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 22-30.
[12] ZHAO Hailong, WANG Hao, FANG Yuqing, MAO Fei, ZHAO Zhangning, TIAN Xiangqi, XU Xinrong, WANG Min, LI Xiuhua. Efficacy of additional idebenone in the treatment of 34 patients with Parkinsons disease with depression [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 38-44.
[13] HUANG Huining, DU Juanjuan, SUN Yi, HOU Yinglong, GAO Mei. Hydrogen sulfide alleviates acute obstructive sleep apnea-induced atrial fibrillation by regulating oxidative stress through glutaredoxin-1 [J]. Journal of Shandong University (Health Sciences), 2022, 60(1): 1-5.
[14] LI Minqi, DU Juan, YANG Panpan, KOU Yuying, LIU Shanshan. Research progress of oxidative stress regulating osteoporosis [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 16-24.
[15] LIU Shudan, ZHANG Feiyan, GUO Songlin, LIANG Xueyun, CHEN Dongmei. Oxymatrine ameliorates oxidative stress injury of HaCaT cells induced by hypoxia ischemia [J]. Journal of Shandong University (Health Sciences), 2021, 59(3): 26-34.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd